You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 114 No. 2, February 1988 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effects of Cisplatin Plus Fluorouracil vs Cisplatin Plus Cytarabine on Head and Neck Squamous Multicellular Tumor Spheroids

Naoyuki Kohno, MD; Takao Ohnuma, MD, PhD; Hugh F. Biller, MD; James F. Holland, MD

Arch Otolaryngol Head Neck Surg. 1988;114(2):157-161.


Abstract

• We compared the efficacy of cisplatin plus fluorouracil vs cisplatin plus cytarabine against HEp-2 head and neck carcinoma cells in monolayer and multicellular tumor spheroid (MTS) systems. Increases in exposure time to cisplatin and fluorouracil from one to 24 hours resulted in approximately tenfold and 1000-fold increases, respectively, in cell lethality for both monolayer and MTS cells. Dose-response curves for cisplatin or fluorouracil on MTS cells closely followed those from monolayer cells, indicating good drug penetration into the MTS core. In contrast, dose-response curves on MTS cells after 24-hour exposure to cisplatin and cytarabine showed progressively lesser efficacy at higher drug concentrations. For monolayer cells, cisplatin plus fluorouracil and cisplatin plus cytarabine were both synergistic, the latter combination more synergistic than the former. For MTS cells, both combinations again showed synergistic interaction at moderate to high effect levels. Heightened synergistic interaction was demonstrated especially with the cisplatin plus cytarabine combination. Thus, the cisplatin plus cytarabine combination was always more synergistic than cisplatin plus fluorouracil. These data may serve as a basis for additional clinical trials of cisplatin plus cytarabine in the treatment of patients with head and neck carcinoma.

(Arch Otolaryngol Head Neck Surg 1988;114:157-161)



Author Affiliations

From the Departments of Neoplastic Diseases (Drs Kohno, Ohnuma, and Holland) and Otolaryngology (Drs Kohno and Biller) and Derald H. Ruttenberg Cancer Center (Drs Kohno, Ohnuma, Biller, and Holland), Mount Sinai School of Medicine, New York.


Footnotes

Accepted for publication Aug 31, 1987.

Read before the 78th annual meeting of the American Association for Cancer Research, Atlanta, May 22, 1987.

Reprint requests to Department of Neoplastic Diseases, Mount Sinai School of Medicine, One Gustave L. Levy P1, New York, NY 10029 (Dr Ohnuma).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Polymer Delivery of Chemotherapy for Squamous Cell Carcinoma of the Head and Neck
Shikani et al.
Arch Otolaryngol Head Neck Surg 1994;120:1242-1247.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.